Expertise in
4
conditions

Philip J. O'connell

92-94 Parramatta Road, 
Camperdown, NSW, AU 
Expertise in
4
conditions
92-94 Parramatta Road, 
Camperdown, NSW, AU 
OverviewLocationsClinical Research

Overview

Philip O'connell practices in Camperdown, Australia. Mr. O'connell is highly rated in 4 conditions, according to our data. His top areas of expertise are Type 1 Diabetes (T1D), Chronic Kidney Disease, Cerebral Hypoxia, Islet Cell Transplantation, and Kidney Transplant.

His clinical research consists of co-authoring 115 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

92-94 Parramatta Road, Camperdown, NSW 2050, Australia
Other Locations
176 Hawkesbury Rd, Sydney, NSW 2145, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
Enrollment Status: Terminated
Publish Date: July 23, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

115 Total Publications

Author Correction: LILRB3 genetic variation is associated with kidney transplant failure in African American recipients.
Author Correction: LILRB3 genetic variation is associated with kidney transplant failure in African American recipients.
Journal: Nature medicine
Published: April 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. O'connell's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile